MEIP - MEI Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.4900
-0.7800 (-18.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.2700
Open3.8100
Bid3.5100 x 800
Ask3.5500 x 1400
Day's Range3.3500 - 3.8465
52 Week Range0.7200 - 4.4600
Volume10,829,501
Avg. Volume2,693,435
Market Cap369.937M
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-0.4720
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.44
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / July 3, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MEI Pharma, Inc. ("MEI Pharma" or "the Company") ...

  • Why MEI Pharma Is Tanking 15.3% Today
    Motley Fool

    Why MEI Pharma Is Tanking 15.3% Today

    What happened Shares in MEI Pharma (NASDAQ: MEIP) are tumbling 15.3% at 11:55 a.m. EDT on Thursday following news its collaboration partner, Helsinn Group, is discontinuing a phase 3 trial of pracinostat in acute myeloid leukemia, or AML.

  • Reuters

    Swiss pharma Helsinn, MEI scrap blood cancer therapy trial

    Shares of MEI Pharma fell nearly 18% to $3.53. The decision comes after an independent committee determined the therapy was unlikely to meet the study's main goal of improving overall survival among Acute Myeloid Leukemia (AML) patients compared to a control group. The study was testing pracinostat in combination with azacitidine in AML patients who are unfit to receive standard intensive chemotherapy.

  • Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%
    Zacks

    Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%

    Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • Hedge Funds Are Souring On MEI Pharma Inc (MEIP)
    Insider Monkey

    Hedge Funds Are Souring On MEI Pharma Inc (MEIP)

    We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

  • 4 Breakout Stocks for Explosive Returns
    Zacks

    4 Breakout Stocks for Explosive Returns

    The first step to selecting the right breakout stock is to calculate its support and resistance level.

  • Billionaire Ken Griffin Pulls the Trigger on These 3 Penny Stocks
    TipRanks

    Billionaire Ken Griffin Pulls the Trigger on These 3 Penny Stocks

    Penny stocks, they divide market watchers like no other. Some investors steer clear of these tickers going for less than $5 apiece, as poor fundamentals or overwhelming headwinds could be keeping them down in the dumps.On the other hand, penny stocks lure the more risk-tolerant. Not only does the bargain price tag mean you get more bang for your buck, but also even minor share price appreciation can yield huge percentage gains. The implication? Major returns for investors.Based on the above, weeding out the long-term underperformers from the penny stocks going for gold can pose a significant challenge. In this case, the activity of legendary stock pickers can provide some inspiration.Among these Wall Street titans is Ken Griffin. The guru, who began trading from his dorm room at Harvard University, went on to found hedge fund Citadel in 1990, with Griffin serving as CEO. Given that the fund now manages over $33 billion in capital, it’s no wonder investor focus locks in on Citadel when moves are made.Currently, “we're in the moving business. So unless we think there's a very clear reason as to why an asset we own is going to appreciate soon, that's just not where we're going to be. And we drove our business away from balance-sheet intensive businesses to – in a sense – all skill-based businesses,” Griffin commented.Taking all of this into consideration, we used TipRanks’ database to find out what the analyst community has to say about three penny stocks that Griffin's fund snapped up recently. It turns out that the analyst consensus has rated each a “Strong Buy." Not to mention substantial upside potential is also on the table.Millendo Therapeutics (MLND)Primarily focused on developing new treatments for endocrine diseases, Millendo Therapeutics wants to address the significant unmet medical needs of patients. At $2.07, its share price could reflect the ideal entry point given everything the company has going for it.Pulling the trigger for the first time, Griffen joined MLND’s growing list of fans. Recently, Citadel bought up 374,653 shares, with the value of this new holding coming in at just under $2 million.Also singing the healthcare name’s praises is Roth Capital analyst Yasmeen Rahimi. At the beginning of May, MLND announced that it expects to have interim data in Q3 2020 from currently enrolled patients in the Phase 2b study evaluating nevanimibe (ATR-101), its ACAT1 inhibitor, in classic congenital adrenal hyperplasia (CAH), which was halted due to COVID-19. This development is especially exciting for the 5-star analyst as she believes success in this indication is very likely.Currently, the only approved treatment option for patients with CAH are glucocorticoid and mineralocorticoid replacement therapies, but these can lead to overtreatment and growth retardation. “Thus, in our view, there remains an urgent need for interventions that can alleviate the serious health risks associated with cortisol deficiency and excessive androgen levels in CAH,” Rahimi said.MLND tackles the condition from a different angle as “nevanimibe's mechanism of action (MOA) utilizes an elegant approach to CAH treatment by working upstream of these pathways and reducing the available reservoir of cholesterol esters, which are used in the synthesis of steroid hormones.” This allows for the suppression of excess steroid production as well as a more selective MOA.Expounding on this, Rahimi noted, “In our view, nevanimibe’s selectivity gives it a major advantage in specifically reducing steroid synthesis in the adrenal cortex, which targets the root cause of CAH... Nevanimibe’s strength lies in its potential to offer an adrenal-targeted approach that can allow patients to better balance their control of excess androgen secretion with the required glucocorticoid replacement therapy.”With data from nevanimibe’s Phase 2a trial demonstrating strong levels of both efficacy and safety, the deal is sealed for Rahimi. To this end, the top analyst rates MLND a Buy along with a $6 price target. This target implies shares could climb 190% higher in the next twelve months. (To watch Rahimi’s track record, click here) Looking at the consensus breakdown, most other analysts are on the same page. With 3 Buys and 1 Hold, the word on the Street is that MLND is a Strong Buy. The $5.25 average price target puts the upside potential at 153%. (See MLND stock analysis on TipRanks)MEI Pharma (MEIP)Hoping to build a top oncology franchise, MEI Pharma boasts a strong development pipeline that includes four compelling drug candidates. Currently going for $3.49 apiece, the share price could present investors with the chance to get in on the action.Not wanting to miss out on an opportunity, Citadel added a new MEIP holding to the fund. Griffin’s fund acquired 1,055,185 shares, with the value of the purchase landing at $1.7 million.Turning now to the analyst community, Wells Fargo’s Jim Birchenough is also optimistic about MEIP’s long-term growth prospects. The 5-star analyst explains that a recent ASCO KOL investor event related to its lead candidate, ME-401, strengthened his bullish thesis.“We continue to view ME-401 as a best-in-class PI3Kδ inhibitor with superior safety and tolerability driving long-term dosing resulting in improved outcomes. We remain confident that the pivotal TIDAL follicular lymphoma (FL) trial will be positive and support product approval in 2021. The recent global alliance with Kyowa Kirin will accelerate development beyond 3rd line-plus FL into earlier stage disease and more broadly into other lymphomas in 2021,” Birchenough commented.Looking at the trial’s design, it utilizes a 60mg once per day dose for two 28-day cycles, which is then followed by a 7-days on 21 days off intermittent dosing schema. This design is important as the intermittent dosing “mitigates against the risk for early discontinuation due to immune-related toxicity secondary to on-target inhibition of regulatory T cell function.” Additionally, should an 83% response rate be achieved, “both duration of disease and progression free survival will be superior to those for approved PI3K inhibitors, ZYDELIG, ALIQOPA and COPIKTRA.”It should be noted that FL has a complicated treatment landscape. However, based on efficacy data for ME-401±rituximab, Birchenough argues that the therapy could be a second-line chemo-free option that’s more easily tolerated.In line with his bullish take, Birchenough reiterated an Overweight call and $13 price target. Should the target be met, a twelve-month gain of 272% could be in store. (To watch Birchenough’s track record, click here) Like Birchenough, other analysts also take a bullish approach. MEIP’s Strong Buy consensus rating breaks down into only Buys, 5, in fact. Given the $11.40 average price target, the upside potential lands at 204%. (See MEIP stock analysis on TipRanks)Kezar Life Sciences Inc. (KZR)Last but not least we have Kezar Life Sciences, which develops treatments for patients with autoimmune diseases and cancer. With encouraging new data supporting its most advanced asset, KZR-616, some think that its $4.96 share price looks like a steal.This appears to be the stance taken by Griffin. Boosting its KZR holding by a whopping 1,338%, Citadel snapped up 859,760 shares. Now at 924,034 shares, the fund’s total stake in the company is valued at over $4 million.Weighing in for H.C. Wainwright, 5-star analyst Raghuram Selvaraju says the recently published interim data from the Phase 1b part of the MISSION trial testing KZR-616 is incredibly promising. Pointing out this readout is most likely one of several data sets from interim analyses, he notes that “improvements were seen across seven measures of disease activity, and two out of two patients with lupus nephritis (LN) experienced a >50% reduction in proteinuria, a biomarker of disease severity.” On top of this, the candidate exhibited a robust safety and tolerability profile at the step-up dose, which could solve the tolerability issues produced by a higher dose.Digging a bit deeper into the results, as of the data cutoff on May 4, the trial had 39 systemic lupus erythematosus (SLE) patients enrolled across five dose cohorts evaluating 45mg and step-up dosing to 60mg weekly for 13 weeks. Out of the patients that finished treatment in cohorts 2a and 2b, a majority saw all seven measures of disease activity improve.Selvaraju added, “Improvement in disease activity persisted following completion of treatment, pointing to sustained impact with KZR-616. We are hopeful that this could prove a harbinger of disease-modifying potential.”Even though COVID-19 has led to significant slowdowns and forced the company to fully pause some of its three KZR-616 studies, the situation may be improving soon, in Selvaraju’s opinion. KZR is still able to conduct trials at private clinics, and it already implemented an in-home nursing solution.It should come as no surprise, then, that Selvaraju stayed with the bulls. In addition to keeping a Buy rating on the stock, the analyst bumped up the price target to $12. This new target suggests shares could soar 148% in the next year. (To watch Selvaraju’s track record, click here)All in all, other analysts echo Selvaraju’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $15 average price target, which is more aggressive than Selvaraju’s, a twelve-month gain of 210% could be in the cards. (See KZR's stock-price forecast on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Go Defensive to Beat Market Turbulence With These 4 Stocks
    Zacks

    Go Defensive to Beat Market Turbulence With These 4 Stocks

    Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.

  • What You Need To Know About The MEI Pharma, Inc. (NASDAQ:MEIP) Analyst Downgrade Today
    Simply Wall St.

    What You Need To Know About The MEI Pharma, Inc. (NASDAQ:MEIP) Analyst Downgrade Today

    One thing we could say about the analysts on MEI Pharma, Inc. (NASDAQ:MEIP) - they aren't optimistic, having just made...

  • Is the Options Market Predicting a Spike in MEI Pharma (MEIP) Stock?
    Zacks

    Is the Options Market Predicting a Spike in MEI Pharma (MEIP) Stock?

    Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.

  • Small Drug Industry Prospects Bright Amid Coronavirus Gloom
    Zacks

    Small Drug Industry Prospects Bright Amid Coronavirus Gloom

    Small Drug Industry Prospects Bright Amid Coronavirus Gloom

  • MEI Pharma to Present at the Jefferies Virtual Healthcare Conference
    PR Newswire

    MEI Pharma to Present at the Jefferies Virtual Healthcare Conference

    MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and business update at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, 2020 at 11:00 AM Eastern Time. The conference is being held in a virtual format.

  • MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program
    PR Newswire

    MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program

    MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst video webcast event on Tuesday, June 2nd, 2020 at 8:00 AM ET following the ASCO20 Virtual Scientific Program. The event will include a review of the ME-401 program, the recent data presented at ASCO20, and commentary from key opinion leader Matthew J. Matasar, M.D., a board-certified medical oncologist/hematologist and Attending Physician, Lymphoma Service, and Medical Director, Memorial Sloan Kettering – Bergen.

  • How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry
    Zacks

    How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry

    MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Top Ranked Momentum Stocks to Buy for May 15th
    Zacks

    Top Ranked Momentum Stocks to Buy for May 15th

    Top Ranked Momentum Stocks to Buy for May 15th

  • MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?
    Zacks

    MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).

  • MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress
    PR Newswire

    MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress

    MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that updated Phase 1b data on ME-401, its investigational oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor drug-candidate in clinical development for the treatment of follicular lymphoma and other B-cell malignancies, will be presented in a poster session at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress to be held June 11 to June 14, 2020.

  • Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes
    PR Newswire

    Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

    Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, and MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced new data from the Phase 2 study evaluating pracinostat, an oral pan-histone deacetylase inhibitor (HDACi), in combination with azacitidine in patients with high and very-high risk myelodysplastic syndromes previously untreated with hypomethylating agents. The study results will be featured in a poster at the American Society of Clinical Oncology 2020 Virtual Scientific Program.

  • Investing.com

    H.C. Wainwright Sticks to Their Buy Rating for MEI Pharma

    H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on MEI Pharma (NASDAQ:MEIP) on Monday, setting a price target of $10, which is approximately 264.96% above the present share price of $2.74.

  • MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Are Pretty Bullish On The Stock After Recent Results
    Simply Wall St.

    MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Are Pretty Bullish On The Stock After Recent Results

    Investors in MEI Pharma, Inc. (NASDAQ:MEIP) had a good week, as its shares rose 3.8% to close at US$2.74 following the...

  • MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights
    PR Newswire

    MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights

    MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended March 31, 2020 and highlighted recent corporate progress.

  • How Does MEI Pharma, Inc. (NASDAQ:MEIP) Affect Your Portfolio Volatility?
    Simply Wall St.

    How Does MEI Pharma, Inc. (NASDAQ:MEIP) Affect Your Portfolio Volatility?

    If you own shares in MEI Pharma, Inc. (NASDAQ:MEIP) then it's worth thinking about how it contributes to the...

  • The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
    Benzinga

    The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs April 14) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Acceleron Pharma Inc (NASDAQ: XLRN) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * Keros Therapeutics Inc (NASDAQ: KROS) (IPOed April 8) * Masimo Corporation (NASDAQ: MASI) * MEI Pharma Inc (NASDAQ: MEIP)(announced a licensing agreement with Japan's Kyowa Kirin for developing its ME-401, which is being evaluated for B-cell malignancies) * Neoleukin Therapeutics Inc (NASDAQ: NLTX) * Neubase Therapeutics Inc (NASDAQ: NBSE) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)(announced appointment of controlling shareholder Robert Duggan as CEO)Down In The Dumps (Biotech Stocks Hitting 52-Week Lows April 14) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)(announced a 1-for-20 reverse stock split, effective close of trading Tuesday) * TherapeuticsMD Inc (NASDAQ: TXMD)See Also: Gilead Analysts Break Down Remdesivir Data Readout From Compassionate UseStocks In Focus Pfenex Says FDA Requests Additional Data For Establishing Bioequivalence Of Osteoporosis Drug To Forteo Pfenex Inc (NYSE: PFNX) said the FDA informed its commercialization partner Alvogen Malta Operations through a General Advice letter, additional comparative use human factors data, especially from Forteo experienced users, would be required before PF708 Therapeutic Equivalence could be determined.Forteo is Eli Lilly And Co's(NYSE: LLY) drug indicated to treat ostmenopausal women with osteoporosis at high risk for fracture."We intend to work closely with Alvogen and the FDA to expeditiously move toward a solution addressing the Agency's expressed views, so that we can submit additional data as soon as possible," said Eef Schimmelpennink, CEO of Pfenex.The company also said it will continue to support Alvogen with its commercial strategy planning in the U.S. while continuing to seek "A" therapeutic equivalence designation.Crinetics Announces 7.15M Common Stock Offering Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) priced its underwritten public offering of 7.15 million shares at $14 per share. All the shares are being offered by the company. The company expects to raise gross proceeds of $100.1 million from the offering. The offering is expected to close on or about April 17.The company said it intends to use the net proceeds to fund the development of paltusotine and other R&D programs, and for working capital and general corporate purposes.Athersys Given Go Ahead To Initiate Midstage Study Of Stem Cell Therapy For Traumatic Injuries Athersys Inc (NASDAQ: ATHX) said the FDA has authorized an IND to initiate a Phase 2 study evaluating its MultiStem cell therapy for early treatment of traumatic injuries and the subsequent complications that result following severe trauma.Applied DNA Ships 5 Vaccine Constructs To Begin Animal Testing In Italy Applied DNA Sciences Inc (NASDAQ: APDN) said it has completed design, qualification, production and shipment of five COVID-19 vaccine candidates to Italy-based Takis Biotech to start preclinical testing immediately. The vaccine candidates, according to the company, were produced by its proprietary PCR-based Linear DNA manufacturing systems."Preliminary animal test results from the plasmid-based vaccine templates, from which Applied DNA's linear DNA-based vaccine constructs were manufactured at scale, were immunogenic and induced a strong production of antibodies across all five vaccine candidates," said Dr. Luigi Aurisicchio, CEO and CSO of Takis Biotech.In pre-market trading, shares were surging up 43.96% to $6.55.Merck Announces U.S. Launch Of Biosimilar For Roche's Popular Breast Cancer Drug Merck & Co., Inc. (NYSE: MRK) announced the U.S. launch of Ontruzant, a biosimilar of the reference biologic medicine Herceptin - Roche Holdings AG's (OTC: RHHBY) breast cancer drug.The company noted that the biosimilar will be available in both 150 mg single-dose vials, priced at WAC of $1,325, and 420mg multiple-dose vials, priced at $3,709. This represented a 15% discount to the current list price of Herceptin.Ontruzant is developed by Samsung Bioepis, with Merck assuming the responsibility of the commercialization of the biosimilar in the U.S.In pre-market trading, Merck shares were slipping 1.44% to $81.65.Mallinckrodt Announces Publication Of Positive Efficacy Data For Acthar Gel Mallinckrodt PLC (NYSE: MNK) announced the publication of findings from a Phase 4 study to assess the safety and efficacy of Acthar Gel in patients with persistently active rheumatoid arthritis, with Acthar Gel demonstrating the potential for effectiveness in achieving low disease activity as assessed by DAS28-ESR2 in patients with active RA despite current treatment with low-dose glucocorticoids and one or two DMARDs.The stock was gaining 1.53% to $3.99 in pre-market trading.Oragenics' Antibiotic Candidate Flunks Midstage Study In Treating Oral Mucositis Oragenics Inc (NYSE: OGEN) said early top-line results of the company's Phase 2 clinical trial of AG013 in oral mucositis in chemoradiation in head and neck cancer patients did not demonstrate statistical significance on the primary endpoint of severe oral mucositis duration when compared to placebo.The stock slumped 46.20% to 43 cents in premarket trading Wednesday.On The Radar Clinical Readouts Vir Biotechnology Inc (NASDAQ: VIR) will present at a Key Opinion leader call an update on its Phase 1/2 hepatitis B virus clinical trial with small interfering ribonucleic acid VIR-2218, Vir had licensed the investigational asset from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).See more from Benzinga * The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • MEI Pharma Appoints Cheryl Cohen, Product Launch and Commercialization Veteran, to its Board of Directors
    PR Newswire

    MEI Pharma Appoints Cheryl Cohen, Product Launch and Commercialization Veteran, to its Board of Directors

    MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the appointment of Cheryl L. Cohen to its board of directors.